News - Novartis, Ultibro Breezhaler

Filter

Popular Filters

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

19-02-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

GermanyNorthern EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryUltibro BreezhalerXoterna Breezhaler

Novartis gains EU and Japan approval for COPD treatments

Novartis gains EU and Japan approval for COPD treatments

24-09-2013

Swiss drug major Novartis has received approval from the European Commission for once-daily Ultibro Breezhaler…

EuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro Breezhaler

Further evidence of Ultibro Breezhaler efficacy showcased at ERS meeting

09-09-2013

Swiss drug major Novartis (NOVN: VX) released date data from new analyses for once-daily Ultibro Breezhaler…

NovartisPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Two CHMP positives for Novartis

29-07-2013

There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

Back to top